ATE293688T1 - Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose- nukleotide - Google Patents
Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose- nukleotideInfo
- Publication number
- ATE293688T1 ATE293688T1 AT01969101T AT01969101T ATE293688T1 AT E293688 T1 ATE293688 T1 AT E293688T1 AT 01969101 T AT01969101 T AT 01969101T AT 01969101 T AT01969101 T AT 01969101T AT E293688 T1 ATE293688 T1 AT E293688T1
- Authority
- AT
- Austria
- Prior art keywords
- arabinonucleotide
- residues
- antisense oligonucleotides
- flanking
- series
- Prior art date
Links
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical class OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 title abstract 4
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title abstract 3
- 239000000074 antisense oligonucleotide Substances 0.000 title abstract 3
- 238000012230 antisense oligonucleotides Methods 0.000 title abstract 3
- HMFHBZSHGGEWLO-HWQSCIPKSA-N L-arabinofuranose Chemical class OC[C@@H]1OC(O)[C@H](O)[C@H]1O HMFHBZSHGGEWLO-HWQSCIPKSA-N 0.000 title 1
- 239000002214 arabinonucleotide Substances 0.000 abstract 6
- 108020004394 Complementary RNA Proteins 0.000 abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 2
- 239000003184 complementary RNA Substances 0.000 abstract 2
- 108020000999 Viral RNA Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
- 230000014616 translation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23041400P | 2000-09-06 | 2000-09-06 | |
| PCT/CA2001/001252 WO2002020773A2 (en) | 2000-09-06 | 2001-09-04 | Chimeric antisense oligonucleotides of arabinofuranose analogues and deoxyribose nucleotides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE293688T1 true ATE293688T1 (de) | 2005-05-15 |
Family
ID=22865132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01969101T ATE293688T1 (de) | 2000-09-06 | 2001-09-04 | Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose- nukleotide |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8178348B2 (de) |
| EP (1) | EP1315807B1 (de) |
| JP (1) | JP2004507272A (de) |
| AT (1) | ATE293688T1 (de) |
| AU (2) | AU8944801A (de) |
| CA (1) | CA2419563C (de) |
| DE (1) | DE60110244T2 (de) |
| WO (1) | WO2002020773A2 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE346918T1 (de) * | 1998-06-19 | 2006-12-15 | Univ Mcgill | Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide |
| DK1470144T3 (da) | 2002-02-01 | 2009-04-06 | Univ Mcgill | Oligonukleotider omfattende alternerende segmenter og anvendelser deraf |
| US20050053981A1 (en) * | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
| MX2007005083A (es) | 2004-10-29 | 2007-10-03 | Topigen Pharmaceuticals Inc | Oligonucleotidos antisentido para tratar alergias y proliferacion celular neoplastica. |
| CA2652539A1 (en) | 2006-05-19 | 2007-11-29 | Topigen Pharmaceuticals Inc. | Oligonucleotides affecting expression of phosphodiesterases |
| EP2285961A4 (de) | 2008-05-15 | 2012-10-17 | Topigen Pharmaceuticals Inc | Oligonukleotide zur behandlung von entzündungen und neoplastischer zellvermehrung |
| CN107083386A (zh) * | 2008-08-25 | 2017-08-22 | 埃克斯雷德制药有限公司 | 阻止结缔组织生长因子的反义核苷酸及其用途 |
| GB201110239D0 (en) | 2011-06-17 | 2011-08-03 | College The | Labelling method |
| HK1200484A1 (zh) | 2011-09-14 | 2015-08-07 | Translate Bio Ma, Inc. | 多聚寡核苷酸化合物 |
| US20150247141A1 (en) | 2012-09-14 | 2015-09-03 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
| CN112969799A (zh) * | 2018-09-26 | 2021-06-15 | 奥姆生命科技公司 | 2′fana修饰的foxp3反义寡核苷酸及其使用方法 |
| WO2020072991A1 (en) * | 2018-10-05 | 2020-04-09 | Ionis Pharmaceuticals, Inc. | Modified oligomeric compounds and uses thereof |
| CN113573717A (zh) | 2019-01-22 | 2021-10-29 | 科罗生物公司 | Rna编辑的寡核苷酸及其用途 |
| AU2020210900B2 (en) * | 2019-01-22 | 2025-04-24 | Korro Bio, Inc. | RNA-editing oligonucleotides and uses thereof |
| CA3127241A1 (en) | 2019-01-22 | 2020-07-30 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| CN114929336A (zh) * | 2019-09-19 | 2022-08-19 | 阿尔奈科学有限责任公司 | 用于调节基因剪接的化合物和方法 |
| CA3240558A1 (en) * | 2021-12-16 | 2023-06-22 | Valerio Therapeutics | New conjugated nucleic acid molecules and their uses |
| CA3245202A1 (en) * | 2022-03-01 | 2023-09-07 | Colorado State University Research Foundation | Targeted control of weeds and invasive plants through the administration of Fana antisense oligonucleotides |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5955589A (en) * | 1991-12-24 | 1999-09-21 | Isis Pharmaceuticals Inc. | Gapped 2' modified oligonucleotides |
| US5808040A (en) * | 1995-01-30 | 1998-09-15 | Yale University | L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides |
| US5968748A (en) * | 1998-03-26 | 1999-10-19 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human HER-2 expression |
| AU3465599A (en) * | 1998-04-01 | 1999-10-18 | Hybridon, Inc. | Mixed-backbone oligonucleotides containing pops blocks to obtain reduced phosphorothioate content |
| ATE346918T1 (de) * | 1998-06-19 | 2006-12-15 | Univ Mcgill | Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide |
-
2001
- 2001-09-04 CA CA2419563A patent/CA2419563C/en not_active Expired - Lifetime
- 2001-09-04 AU AU8944801A patent/AU8944801A/xx active Pending
- 2001-09-04 WO PCT/CA2001/001252 patent/WO2002020773A2/en not_active Ceased
- 2001-09-04 US US10/363,768 patent/US8178348B2/en not_active Expired - Fee Related
- 2001-09-04 EP EP01969101A patent/EP1315807B1/de not_active Expired - Lifetime
- 2001-09-04 AT AT01969101T patent/ATE293688T1/de not_active IP Right Cessation
- 2001-09-04 JP JP2002525780A patent/JP2004507272A/ja active Pending
- 2001-09-04 DE DE60110244T patent/DE60110244T2/de not_active Expired - Lifetime
- 2001-09-04 AU AU2001289448A patent/AU2001289448B8/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU8944801A (en) | 2002-03-22 |
| WO2002020773A2 (en) | 2002-03-14 |
| EP1315807A2 (de) | 2003-06-04 |
| DE60110244T2 (de) | 2006-01-19 |
| CA2419563A1 (en) | 2002-03-14 |
| CA2419563C (en) | 2018-03-20 |
| AU2001289448B8 (en) | 2006-08-10 |
| US20040038399A1 (en) | 2004-02-26 |
| AU2001289448B2 (en) | 2006-03-16 |
| EP1315807B1 (de) | 2005-04-20 |
| WO2002020773A3 (en) | 2003-01-23 |
| US8178348B2 (en) | 2012-05-15 |
| JP2004507272A (ja) | 2004-03-11 |
| DE60110244D1 (de) | 2005-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60110244D1 (de) | Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose-nukleotide | |
| DE69934227D1 (de) | Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide | |
| Daubendiek et al. | Generation of catalytic RNAs by rolling transcription of synthetic DNA nanocircles | |
| WO2004015075A3 (en) | SHORT INTERFERING RNAs HAVING A HAIRPIN STRUCTURE CONTAINING A NON-NUCLEOTIDE LOOP | |
| TNSN08252A1 (en) | Sirna anti myosine va et depigmentation de la peau | |
| ZA200304500B (en) | Method for inhibiting the expression of a target gene and medicament for treating a tumor disease. | |
| Matteucci et al. | Deoxyoligonucleotides bearing neutral analogs of phosphodiester linkages recognize duplex DNA via triple-helix formation | |
| Patel et al. | Formation of chimeric DNA primer extension products by template switching onto an annealed downstream oligonucleotide. | |
| WO2001032832A3 (en) | Antisense inhibition of nucleolin expression | |
| JP2003219893A5 (de) | ||
| EP1513859A4 (de) | Kinasesuppressor der ras-inaktivierung zur therapie von durch ras vermittelter tumorgenese | |
| WO2001083513A3 (en) | Antisense modulation of inhibitor of dna binding-1 expression | |
| EP3040423A3 (de) | Mikro-rna und verwendung davon | |
| KR20040028771A (ko) | 비시엘-2 디엔에이 효소 | |
| WO2000008140A3 (en) | Antisense oligonucleotides for the inhibition of vegf expression | |
| DE602004031946D1 (de) | Das künstliche cpg single strand deoxidation-oligonukleotid und dessen antivirale anwendungen | |
| EP1697498A4 (de) | Kinasesuppressor der ras-inaktivierung zur therapie von durch ras vermittelter tumorgenese | |
| WO2003031459A3 (de) | Modulation der expression stat-1-abhängiger gene | |
| CA2331333A1 (en) | Antisense oligonucleotide constructs based on .beta.-arabinofuranose and its analogues | |
| JP2006514546A5 (de) | ||
| Hovig et al. | Optimization of hammerhead ribozymes for the cleavage of S100A4 (CAPL) mRNA | |
| WO2001051670A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof | |
| IT1320168B1 (it) | Oligonucleotidi sintetici in grado di indurre il differenziamentoeritroide. | |
| CA2330570C (en) | Nucleic acid enzyme for rna cleavage | |
| Temsamani et al. | Inhibition of in vitro transcription by oligodeoxynucleotides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |